Improved hypertrophic obstructive cardiomyopathy by left ventricular apex epicardial pacing

Internal Medicine

Volumn 43, Issue 4, 2004, Pages 295-299

  Yufu, Kunio ^a,c   Takahashi, Naohiko ^a   Ooie, Tatsuhiko ^a   Shigematsu, Sakuji ^a   Hara, Masahide ^a   Sako, Hidenori ^a   Miyamoto, Shinji ^a   Hadama, Tetsuo ^a   Tsuchiya, Takeshi ^b   Honda, Toshihiro ^b   Yoshimatsu, Hironobu ^a   Saikawa, Tetsunori ^a  

^a OITA UNIVERSITY   (Japan)

^b SAISEIKAI KUMAMOTO HOSPITAL   (Japan)

^c OITA RED CROSS HOSPITAL   (Japan)

Author keywords

Epicardial pacing; HOCM; Pacemaker

Indexed keywords

ATENOLOL; VERAPAMIL;

ADULT; ARTICLE; ARTIFICIAL HEART PACEMAKER; CASE REPORT; CLINICAL EXAMINATION; DISEASE SEVERITY; DOPPLER ECHOCARDIOGRAPHY; DYSPNEA; FEMALE; HEART CATHETERIZATION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE OUTFLOW TRACT; HEART PACING; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; PRESSURE GRADIENT; REST; SURGICAL TECHNIQUE; SYMPTOM; TREATMENT OUTCOME;

AORTA; CARDIAC PACING, ARTIFICIAL; CARDIOMYOPATHY, HYPERTROPHIC; FEMALE; GATED BLOOD-POOL IMAGING; HUMANS; MIDDLE AGED; VENTRICULAR FUNCTION, LEFT; VENTRICULAR PRESSURE;

EID: 20244387381     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.43.295     Document Type: Article

References (19)

1. Flamm MD, Harrison DC, Hancock EW. Muscular subaortic stenosis. Prevention of outflow obstruction with propranolol. Circulation 38: 846-858, 1968.
2. Chatterjee K. Calcium antagonist agents in hypertrophic cardiomyopathy. Am J Cardiol 59: 146B-152B, 1987.
3. Rishi F, Hulse JE, Auld DO, et al. Effects of dual-chamber pacing for pediatric patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 29: 734-740, 1997.
4. Jeanrenaud X, Goy J-J, Kappenberger L. Effect of dual-chamber pacing in hypertrophic obstructive cardiomyopathy. Lancet 339: 1318-1323, 1992.
5. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 346: 211-214, 1995.
6. Tsuchikane E, Nakamura T, Yamazaki K, et al. Transluminal percutaneous septal myocardial ablation in a patient with hypertrophic obstructive cardiomyopathy. Jpn Circ J 62: 537-540, 1998.
7. MacIntosh CL, Maron BJ. Current operative treatment of obstructive hypertrophic cardiomyopathy. Circulation 78: 487-495, 1988.
8. Seiler C, Hess OM, Schoenbeck M, et al. Long-term follow-up of medical versus surgical therapy for hypertrophic cardiomyopathy: a retrospective study. J Am Coll Cardiol 17: 634-642, 1991.
9. Seggewiss H, Faber L, Gleichman U, Fassbender D, Schmidt HK, Strick S. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute hemodynamic and clinical results. Circulation 96 (Suppl I): I-218, 1997.
10. Matsumoto K. Therapy of HOCM by DDD pacemaker. Cardioangiology 52: 48-52, 2002 (in Japanese).
11. Borer JS, Bacharach SL, Green MV, et al. Effect of septal myotomy and myectomy on left ventricular systolic function at rest and during exercise in patients with IHSS. Circulation 60: 82-87, 1979.
12. Nishimura RA, Hayes DL, Ilstrup DM, Holmes DR Jr, Tajik AJ. Effect of dual-chamber pacing on systolic and diastolic function in patients with hypertrophic cardiomyopathy: acute Doppler echocardiographic and catheterization hemodynamic study. J Am Coll Cardiol 27: 421-430, 1996.
13. Matsumoto K, Saito J, Mukosaka K, et al. Influences of changing the pacing site on the hemodynamic improvement by DDD pacing in patients with hypertrophic obstructive cardiomyopathy. Circulation 88 (Suppl I): 1-210, 1993.
14. Gadler F, Linde C, Juhlin-Dannfeldt A, Ribeiro A, Ryden L. Influence of right ventricular pacing site on left ventricular outflow tract obstruction in patients with hypertrophic: obstructive cardiomyopathy. J Am Coll Cardiol 27: 1219-1224, 1996.
15. Fananapazir L, Cannon RO III, Tripodi D, Panza JA. Impact of dual-chamber permanent pacing in patients with obstructive hypertrophic cardiomyopathy with symptoms refractory to verapamil and β -adrenergic blocker therapy. Circulation 85: 2149-2161, 1992.
16. Kappenberger LJ, Linde C, Jeanrenaud X, et al. Clinical progress after randomized on/off pacemaker treatment for hypertrophic obstructive cardiomyopathy. Pacing in Cardiomyopathy (PIC) Study Group. Europace 1: 77-84, 1999.
17. Hamada. M, Shigematsu Y, Ikeda S, et al. Class Ia antiarhythmic drug cibenzoline: a new approach to the medical treatment of hypertrophic obstructive cardiomyopathy. Circulation 96: 1520-1524, 1997.
18. Hiasa G, Hamada. M, Shigematsu Y, et al. Attenuation of biventricular pressure gradients by cibenzoline in an 18-year-old patient with hypertrophic obstructive cardiomyopathy. Circ J 66: 1173-1175, 2002.
19. Hamada M, Shigematsu Y, Hara Y, et al. Antiarrhythmic drug, cibenzoline, can directly improve the left ventricular diastolic function in patients with hypertrophic cardiomyopathy. Jpn Circ 165: 531-538, 2001.